Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Helmut Gunther Rennke, M.D.

Co-Author

This page shows the publications co-authored by Helmut Rennke and Barry Brenner.
Connection Strength

1.145
  1. Ots M, Troy JL, Rennke HG, Mackenzie HS, Brenner BM. Impact of the supplementation of kidney mass on blood pressure and progression of kidney disease. Nephrol Dial Transplant. 2004 Feb; 19(2):337-41.
    View in: PubMed
    Score: 0.079
  2. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol. 2001 Jun; 12(6):1315-25.
    View in: PubMed
    Score: 0.066
  3. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol. 1998 Feb; 9(2):224-30.
    View in: PubMed
    Score: 0.052
  4. Mackenzie HS, Ziai F, Nagano H, Azuma H, Troy JL, Rennke HG, Tilney NL, Brenner BM. Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats. J Hypertens Suppl. 1997 Dec; 15(6):S21-5.
    View in: PubMed
    Score: 0.051
  5. Mackenzie HS, Azuma H, Troy JL, Rennke HG, Tilney NL, Brenner BM. Augmenting kidney mass at transplantation abrogates chronic renal allograft injury in rats. Proc Assoc Am Physicians. 1996 Mar; 108(2):127-33.
    View in: PubMed
    Score: 0.046
  6. Mackenzie HS, Azuma H, Rennke HG, Tilney NL, Brenner BM. Renal mass as a determinant of late allograft outcome: insights from experimental studies in rats. Kidney Int Suppl. 1995 Dec; 52:S38-42.
    View in: PubMed
    Score: 0.045
  7. Mackenzie HS, Troy JL, Rennke HG, Brenner BM. TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens Suppl. 1994 Nov; 12(9):S11-6.
    View in: PubMed
    Score: 0.042
  8. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int. 1994 Aug; 46(2):396-404.
    View in: PubMed
    Score: 0.041
  9. Simons JL, Provoost AP, De Keijzer MH, Anderson S, Rennke HG, Brenner BM. Pathogenesis of glomerular injury in the fawn-hooded rat: effect of unilateral nephrectomy. J Am Soc Nephrol. 1993 Dec; 4(6):1362-70.
    View in: PubMed
    Score: 0.039
  10. Simons JL, Provoost AP, Anderson S, Troy JL, Rennke HG, Sandstrom DJ, Brenner BM. Pathogenesis of glomerular injury in the fawn-hooded rat: early glomerular capillary hypertension predicts glomerular sclerosis. J Am Soc Nephrol. 1993 May; 3(11):1775-82.
    View in: PubMed
    Score: 0.037
  11. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. 1992 Apr; 41(4):891-7.
    View in: PubMed
    Score: 0.035
  12. Lafferty HM, Garcia DL, Rennke HG, Troy JL, Anderson S, Brenner BM. Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension. J Am Soc Nephrol. 1991 Apr; 1(10):1180-5.
    View in: PubMed
    Score: 0.032
  13. Bridges CR, Rennke HG, Deen WM, Troy JL, Brenner BM. Reversible hexadimethrine-induced alterations in glomerular structure and permeability. J Am Soc Nephrol. 1991 Mar; 1(9):1095-108.
    View in: PubMed
    Score: 0.032
  14. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989 Oct; 36(4):526-36.
    View in: PubMed
    Score: 0.029
  15. Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A. 1988 Aug; 85(16):6142-6.
    View in: PubMed
    Score: 0.027
  16. Zatz R, Anderson S, Meyer TW, Dunn BR, Rennke HG, Brenner BM. Lowering of arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney Int Suppl. 1987 May; 20:S123-9.
    View in: PubMed
    Score: 0.025
  17. Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int. 1987 Mar; 31(3):752-9.
    View in: PubMed
    Score: 0.024
  18. Anderson S, Rennke HG, Brenner BM. Antihypertensive therapy must control glomerular hypertension to limit glomerular injury. J Hypertens Suppl. 1986 Dec; 4(5):S242-4.
    View in: PubMed
    Score: 0.024
  19. Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury in renal ablation. J Hypertens Suppl. 1986 Dec; 4(5):S239-41.
    View in: PubMed
    Score: 0.024
  20. Dunn BR, Zatz R, Rennke HG, Meyer TW, Anderson S, Brenner BM. Prevention of glomerular capillary hypertension in experimental diabetes mellitus obviates functional and structural glomerular injury. J Hypertens Suppl. 1986 Dec; 4(5):S251-4.
    View in: PubMed
    Score: 0.024
  21. Hostetter TH, Meyer TW, Rennke HG, Brenner BM. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 1986 Oct; 30(4):509-17.
    View in: PubMed
    Score: 0.024
  22. Badr KF, Kelley VE, Rennke HG, Brenner BM. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int. 1986 Oct; 30(4):474-80.
    View in: PubMed
    Score: 0.024
  23. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986 Jun; 77(6):1925-30.
    View in: PubMed
    Score: 0.023
  24. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986 Jun; 77(6):1993-2000.
    View in: PubMed
    Score: 0.023
  25. Meyer TW, Anderson S, Rennke HG, Brenner BM. Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency. Am J Med. 1985 Sep 27; 79(3C):31-6.
    View in: PubMed
    Score: 0.022
  26. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A. 1985 Sep; 82(17):5963-7.
    View in: PubMed
    Score: 0.022
  27. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985 Aug; 76(2):612-9.
    View in: PubMed
    Score: 0.022
  28. Dworkin LD, Hostetter TH, Rennke HG, Brenner BM. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest. 1984 May; 73(5):1448-61.
    View in: PubMed
    Score: 0.020
  29. Skorecki KL, Ballermann BJ, Rennke HG, Brenner BM. Angiotensin II receptor regulation in isolated renal glomeruli. Fed Proc. 1983 Nov; 42(14):3064-70.
    View in: PubMed
    Score: 0.019
  30. Ichikawa I, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL, Lechene CP, Brenner BM. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest. 1983 Jan; 71(1):91-103.
    View in: PubMed
    Score: 0.018
  31. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982 Mar; 72(3):375-80.
    View in: PubMed
    Score: 0.017
  32. Hostetter TH, Rennke HG, Brenner BM. Compensatory renal hemodynamic injury: a final common pathway of residual nephron destruction. Am J Kidney Dis. 1982 Mar; 1(5):310-4.
    View in: PubMed
    Score: 0.017
  33. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981 Jul; 241(1):F85-93.
    View in: PubMed
    Score: 0.016
  34. Schor N, Ichikawa I, Rennke HG, Troy JL, Brenner BM. Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int. 1981 Feb; 19(2):288-96.
    View in: PubMed
    Score: 0.016
  35. Taal MW, Chertow GM, Rennke HG, Gurnani A, Jiang T, Shahsafaei A, Troy JL, Brenner BM, Mackenzie HS. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol. 2001 Feb; 280(2):F343-55.
    View in: PubMed
    Score: 0.016
  36. Brenner BM, Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol Suppl (Copenh). 1981; 242:7-10.
    View in: PubMed
    Score: 0.016
  37. Ziai F, Nagano H, Kusaka M, Coito AJ, Troy JL, Nadeau KC, Rennke HG, Tilney NL, Brenner BM, MacKenzie HS. Renal allograft protection with losartan in Fisher-->Lewis rats: hemodynamics, macrophages, and cytokines. Kidney Int. 2000 Jun; 57(6):2618-25.
    View in: PubMed
    Score: 0.015
  38. Ziai F, Ots M, Provoost AP, Troy JL, Rennke HG, Brenner BM, Mackenzie HS. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int Suppl. 1996 Dec; 57:S132-6.
    View in: PubMed
    Score: 0.012
  39. Mackenzie HS, Tullius SG, Heemann UW, Azuma H, Rennke HG, Brenner BM, Tilney NL. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest. 1994 Nov; 94(5):2148-52.
    View in: PubMed
    Score: 0.010
  40. García DL, Rennke HG, Brenner BM, Anderson S. Glucocorticoids amplify glomerular injury in rats with renal ablation. Am J Hypertens. 1988 Jan; 1(1):54-7.
    View in: PubMed
    Score: 0.006
  41. Garcia DL, Rennke HG, Brenner BM, Anderson S. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation. J Clin Invest. 1987 Sep; 80(3):867-74.
    View in: PubMed
    Score: 0.006
  42. Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int. 1982 Aug; 22(2):112-26.
    View in: PubMed
    Score: 0.004
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.